Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infections

Infection and Immunity

Volumn 70, Issue 10, 2002, Pages 5715-5720

  Li, Jian ^a   Padigel, Udaikumar M ^a   Scott, Phillip ^a   Farrell, Jay P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 4; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA CHAIN; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOWN REGULATION; DRUG RESPONSE; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; INFECTION RESISTANCE; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TH1 CELL; TH2 CELL;

ANIMALS; FEMALE; INDOMETHACIN; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROSTAGLANDINS; TH1 CELLS; TH2 CELLS;

EID: 0036784673     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.10.5715-5720.2002     Document Type: Article

References (38)

1. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R gene expression at multiple levels
2. Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism
3. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines
4. IL-4 induces a Th2 response in Leishmania major-infected mice
5. Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major
6. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines
7. Single gene control of resistance to cutaneous leishmaniasis in mice
8. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice
9. 15N]nitrate in biological fluids
10. Interleukin 2 is necessary for progression of leishmaniasis in susceptible murine hosts
11. Reciprocal expression of interferon γ for interleukin 4 during the resolution or progression of murine leishmaniasis
12. Recombinant interleukin 12 cures mice infected with Leishmania major
13. Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-γ level of activated human CD4+ T cells
14. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12
15. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease
16. Immunological regulation of experimental cutaneous leishmaniasis. I. Immunogenetic aspects of susceptibility to Leishmania tropica in mice
17. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer
18. The role of IL-10 in promoting disease progression in leishmaniasis
19. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5
20. Anti-TGF-β treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production
21. Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production
22. Murine cutaneous leishmaniasis: Susceptibility correlates with differential expansion of helper T-cell subsets
23. Regulation of interleukin 2 synthesis by cAMP in human T cells
24. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and pentostam
25. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th-1-like responses
26. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling
27. In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards aTh1 type in susceptible BALB/c mice infected with Leishmania mexicana
28. A new view of prostaglandin E regulation of the immune response
29. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes
30. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism
31. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis
32. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
33. Experimental cutaneous leishmaniasis. I. Non-specific immunodepression in BALB/C mice infected with Leishmania tropica
34. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes
35. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response
36. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice
37. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production
38. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness